| RRC ID |
51628
|
| 著者 |
Anindita PD, Sasaki M, Nobori H, Sato A, Carr M, Ito N, Sugiyama M, Orba Y, Sawa H.
|
| タイトル |
Generation of recombinant rabies viruses encoding NanoLuc luciferase for antiviral activity assays.
|
| ジャーナル |
Virus Res
|
| Abstract |
Rabies is an invariably fatal disease caused by Rabies virus (RABV), a member of the family Rhabdoviridae, genus Lyssavirus. Once central nervous infection occurs and symptoms develop, the case fatality rate approaches 100% despite availability of post-exposure prophylaxis. Therefore, new antiviral therapies for rabies are urgently required. Antivirals which can inhibit virus replication can be identified through screening of small compounds, however, as RABV infection does not generate easily discernible cytopathic effects in vitro, cell viability assays may not be feasible to observe antiviral activity of small compounds against RABV. In this study, recombinant RABVs (rRABVs) encoding NanoLuc luciferase (NanoLuc) were generated to facilitate the screening of small compound libraries. NanoLuc expression was confirmed in single-step growth cures of virus infection and showed that the rRABVs were capable of viral replication without decrease of luciferase activity through ten serial passages. Furthermore, the rRABVs were able to quantify the antiviral activity of the nucleoside analogue ribavirin against RABV in vitro. These findings confirm the potential of the rRABV encoding NanoLuc system to facilitate screening of small compounds to inhibit RABV infection.
|
| 巻・号 |
215
|
| ページ |
121-8
|
| 公開日 |
2016-4-2
|
| DOI |
10.1016/j.virusres.2016.02.002
|
| PII |
S0168-1702(16)30100-9
|
| PMID |
26869397
|
| MeSH |
Antiviral Agents / isolation & purification*
Drug Evaluation, Preclinical / methods*
Genes, Reporter*
Luciferases / analysis*
Luciferases / genetics
Rabies virus / drug effects*
Rabies virus / genetics
Rabies virus / growth & development*
Staining and Labeling / methods*
|
| IF |
2.934
|
| 引用数 |
10
|
| リソース情報 |
| ヒト・動物細胞 |
SK-N-SH(RCB0426) |
